Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Change in Cash (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Change in Cash for 5 consecutive years, with -$23.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Cash fell 1519.15% year-over-year to -$23.6 million, compared with a TTM value of -$18.7 million through Dec 2025, up 81.05%, and an annual FY2025 reading of -$18.7 million, up 81.05% over the prior year.
  • Change in Cash was -$23.6 million for Q4 2025 at Aligos Therapeutics, down from $23.3 million in the prior quarter.
  • Across five years, Change in Cash topped out at $65.3 million in Q4 2023 and bottomed at -$111.4 million in Q1 2024.
  • Average Change in Cash over 5 years is -$10.1 million, with a median of -$7.4 million recorded in 2022.
  • The sharpest move saw Change in Cash surged 1390.45% in 2023, then crashed 4551.65% in 2024.
  • Year by year, Change in Cash stood at -$53.4 million in 2021, then soared by 90.53% to -$5.1 million in 2022, then soared by 1390.45% to $65.3 million in 2023, then tumbled by 97.45% to $1.7 million in 2024, then tumbled by 1519.15% to -$23.6 million in 2025.
  • Business Quant data shows Change in Cash for ALGS at -$23.6 million in Q4 2025, $23.3 million in Q3 2025, and -$55.1 million in Q2 2025.